MedTrace Logo

Tricaprilin In Age-Associated Memory Impairment

NCT00355550 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2020-09-18

No results posted yet for this study

Summary

The purpose of this study is to determine whether tricaprilin, a compound that increases energy availability in the brain, improves memory in older adults with "normal" loss of memory abilities since early adult life.

Conditions

  • Age-Associated Memory Impairment

Interventions

DRUG

Tricaprilin

Powder formulation will be mixed in a liquid (approximately 8 oz).

OTHER

Placebo

Powder formulation will be mixed in a liquid (approximately 8 oz).

Sponsors & Collaborators

  • Cerecin

    lead INDUSTRY

Principal Investigators

  • Samuel Henderson, PhD · Cerecin

  • Thomas H. Crook III, PhD · Psychologix, Inc.

  • Thomas Hochadel, Pharm.D. · Advanced Research Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2007-06-30
Completion
2007-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00355550 on ClinicalTrials.gov